Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Celecoxib/ciprofloxacin - NeuroSense Therapeutics

Next Previous
Search
Drug Profile

Celecoxib/ciprofloxacin - NeuroSense Therapeutics

Alternative Names: Ciprofloxacin/celecoxib - NeuroSense Therapeutics; CogniC; PrimeC; PrimeC-ER; StabiliC

Latest Information Update: 09 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeuroSense Therapeutics
  • Class Anti-infectives; Antibacterials; Antidementias; Antimigraines; Antineoplastics; Antiparkinsonians; Antirheumatics; Cyclopropanes; Fluoroquinolones; Neuroprotectants; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Piperazines; Pyrazoles; Small molecules; Sulfonamides
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; DNA gyrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Amyotrophic lateral sclerosis
  • Phase II Alzheimer's disease
  • Phase I Parkinson's disease

Most Recent Events

  • 25 Mar 2025 NeuroSense Therapeutics receives positive feedback from US FDA for Celecoxib/ciprofloxacin for phase-III trial in Amyotrophic lateral sclerosis
  • 20 Mar 2025 NeuroSense Therapeutics seeks regulatory approval with Health Canada for Amyotrophic lateral sclerosis in H1 2026
  • 23 Dec 2024 NeuroSense Therapeutics enters into binding term sheet agreement with Undisclosed company to advance Celecoxib/ciprofloxacin for amyotrophic lateral sclerosis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top